September meeting. FDA wants us to combine both AA and Full Approval sessions into 1 meeting instead of 2 separate meetings. KNN how to do both of them within a 60 min meeting? I think better focus on AA liow as Full Approval seems like a long shot to me due to trial placebo issues.

Post removed.Why?

Posted by Balian de Ibelin > 17 hours ago | Report Abuse
no worries
tomorrow back to 4.60
--------------


A day trading whale. One day's lunch at a time.

Which territory? UAE + UK + USA + EU + CHINA (royal flush) all in, confirm 6.50 no problem

If...

Post removed.Why?

@neohts, its maybank IB again! 😀

Last round was rights/ warrant exercise at usd1.5b but its for the very hardcore brave shareholders like ATK to swop in n bet showhand buy very big. Taurx still has reasonably good cash level with no cash burning clinical trials anytime soon. I think next fund raising will be after securing as many CAs as possible to bring up value first, then do a pre-ipo fund raising.

After UK approval usd15b valuation confirm way to high la. If UK + EU + China CAs secured (global mkt ex-usa), maybe usd15b can. Maybank analyst siow kia, not too long ago put taurx at usd1b value. Need to see if UK giving us Full Approval or Conditional Approval.

Posted by Michaelchan2024 > 2 hours ago | Report Abuse
Actually, I am not a teacher. I just enjoy discussing and learning about trading.
-----------

The first lesson for stock trading is cutloss. Not easy to master this aspect as it is against human nature. When time to cutloss decisively, most amateurs will be hoping for a rebound, invariably leading to bigger losses.

Posted by Michaelchan2024 > 15 minutes ago | Report Abuse
Actually, as a long-term investor, I focus more on understanding long-term trends and making strategic decisions rather than quick trading moves 😀
----------------


Chart wise, no meaningful long term trend for this stock for now. 4 years after covid crash, still stuck range bound from abt 4.00 to 5.20 zones over the past 3 years.

Real traders dont like to talk too much rubbish. Their focus have always been to recognise the trends and make real money out from it. Immediately Buy, Immediately Huat.

https://www.straitstimes.com/world/united-states/donald-trump-shot-in-right-ear-at-rally-secret-service-says-suspected-shooter-is-dead
Win liow. Maciam chen shui bian who staged his own assasination back then in the Taiwanese presidential elections.

The way Trump pumped his fist to the crowd after the failed assassination like a reality show 😅😅😅

Daniel G. Aaron, MD, JD @MedlawDan


My aunt, on Leqembi for early Alzheimer's, just died.
She suffered an hours-long seizure in her bed. Her friend broke into the apartment and got medical help. Discovered to have many brain microhemorrhages and edema. Dead within 24 hours.
12:52 AM · Jul 11, 2024


https://x.com/MedlawDan/status/1811081139257483582


More to come. Many more will be permanently harmed by severe brain bleeding + accelerated brain shrinkage.

Posted by Michaelchan2024 > 4 hours ago | Report Abuse
ATK is selling ..to push down GenB's share price.
-----------

Please la @Michael, which stock market guru taught you to buy high sell low??? If Im trading this stock recently, I would have sold at 4.80+. Some months ago there were people here talking abt selling at 5.20, 5.50, 5.80 etc. I knew most of the time the crowd will get it wrong and my chart is telling me around 4.90 is the conviction sell zone.

Following GenS stock price behaviour. Those who bought over the past 2 months after good GenS result all kena trapped high liow. Treacherous stock market.

Posted by Michaelchan2024 > 2 hours ago | Report Abuse
Run
---------

Good call earlier today @Michael your reading of price action has improved 😄

Wah @michael studying charts n TA over the weekend? 😀

Posted by neohts > 1 day ago | Report Abuse
that Thestar.com news is for ELI Lilly.
--------------

Specially for you @neohts. Lecanemab and Donanemab as Therapies for Alzheimer’s Disease: An Illustrated Perspective on the Data

Alberto J. Espay,1 Kasper P. Kepp,2 and Karl Herrup3
https://www.eneuro.org/content/eneuro/11/7/ENEURO.0319-23.2024.full.pdf


This paper should have elaborated more on accelerated brain shrinkage aspect of Mab class of drugs. Brain neurons dying at faster rate, meaning these treatments are definitely going in the wrong direction. Its a known fact that AD brains shrink faster than normal brains as this rate of brain shrinkage is the purest form of physical biomarker whether the drug is working well or not. These drugs are just giving weak symptomatic effect for 12 months, something Aricept can do much better 25 years ago. Beyond 12 months, the downward slopes shown on graphs are both parallel sloping, indicating these are just symptomatic drugs and not disease modifying as claimed. There has to be some serious brain damage done to those patients here, the real effects can only be seen after a few years of using these drugs.

Posted by neohts > 1 hour ago | Report Abuse
that Thestar.com news is for ELI Lilly.
----------

I know. I replied with links abt the truth of Donanemab. Pay abt US$50k/yr actual treatment for a useless intravenous drug with numerous PET / MRI scans and consultations + iffy trial results (see how they calculate final trial result by excluding those serious side effects/death patients who dropped out trial) + brain bleeding + accelerated brain shrinkage. Generic Aricept drug can produce even better results at 2% of actual treatment cost. Thats a real solid advancement not for Science but purely for doctors' and drug developer's profit! 👏👏👏

July 1, 2024 02:40 JST
TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked to symptoms, aiming to release it in the U.S. by fiscal 2030, Nikkei has learned.

Small-scale clinical trials are underway to confirm the safety of the drug candidate, which targets tau proteins. Such drugs, though difficult to develop, are expected to be highly effective if successful.

https://asia.nikkei.com/Business/Pharmaceuticals/Japan-s-Eisai-aims-for-2030-U.S.-release-of-new-Alzheimer-s-drug?del_type=4&pub_date=20240702070000&seq_num=21&si=13105016
--------------


We discovered this fact during 1980s, now then amyloid drug developers realise targeting Tau can produce much more powerful results. We are lightyears ahead of any real clinically credible AD drug.

https://x.com/AlbertoEspay/status/1800638243056058709

https://x.com/AlbertoEspay/status/1806646390031802876

https://x.com/DanClintonRN/status/1801414681883500698?t=quIksYT-SopFLU0Lhc25Nw&s=08

Then why are prescription drug companies still so profitable? @Balian can choose to consume fake prescription drugs sold at back alley. I will choose the real drug covered by medical insurance.

Posted by AngTayKor > 2024-01-27 02:13 | Report Abuse

Posted by Kikilala3188 > | Report Abuse
Taurx when will it be announcing? Especially U.K. FDA approval
---------------

ATK: UK MHRA's final decision on CA is unlikely to be within 2024. We still have to file in more submissions which will take abt 5 to 6 months to complete it, followed by another 6 to 9 months for the regulator's final decision.

FDA delayed our Type C meeting request (supposed to be end Jan, before Taurx AGM on 6 Feb @6pm). We are not even sure if FDA will agree to consider HMTM using the Accelerated Approval pathway. If yes, I think FDA's final decision for AA will probably be at least 1.5yrs away.
------------------


@Michael, my post dated 27/01/2024 accurate or not? Today, 01/07/2024, Taurx finally announced that they have completed UK submissions.

Post removed.Why?

Posted by KooSan > 6 minutes ago | Report Abuse
And after MAA? What is next? Another trial?
------------

If approve means can commercialise the drug liow. Commonwealth countries including Malaysia and Singapore can follow MHRA's decision

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
Businesswire July 01, 2024

Posted by Michaelchan2024 > 1 hour ago | Report Abuse
ATK's peculiar behavior is that he always tends to tell people to sell, which is typical of short sellers..
--------------

Its all in your mind @Michael. When Im talking history events like past RPTs, LKT sold huge volumes above 5.20 or some occasional negative things, perma bulls will think that Im preaching for everyone to sell. The crowd forgets things very quickly including my bullish Q1 profit forecast of rm600m before the actual Q1 result. They often will choose to retain info according to the state of their fickle mind. To set the record straight, I have never shorted a single stock of GenB. I depend on my own charting skills to trade. I think it is naive to think that posting fear mongering / super bullish posts here in i3 will influence the stock price.

Posted by Michaelchan2024 > 23 minutes ago | Report Abuse
ATK is always ATK. A good storyteller.
--------------

@Michael. it is not a glamorous thing to publicly declare here that I am very cash poor now and no money to trade stocks.

Posted by Michaelchan2024 > 1 hour ago | Report Abuse
@ATK, you mentioned you don't hold any Genting shares. However, what puzzles me is why you are here on the Genting forum?
-----------

Still observing price action and reaction so my trading skill not rusty + how the crowd is thinking for this stock. To become a better boyfriend, you need to understand your girlfriend very well. To trade a stock well, you need to understand the behaviour of the stock well. I still manage to nail the important top (5.20 zone) and bottom (4.45 zone) for this stock during 2024. Call this a trader's life long learning process, Im forever a student of the stock market. I treat this business very seriously. I trade to win money.

No money now, all showhand into Taurx, which I believe can give me much higher returns than stock trading. But some day I will take back all my Taurx investment capital and start stock trading business again.

Dont scare those seatrium investors leh... but in the stock mkt, never say never!

Seatrium a little risky now @michael.

This stock must be suffering from @Michaelchan nonstop cheering fatigue la.

GenS broke strong support. Mkt see its Rm865m Q1 profit no up?

For the past 3 yrs, this stock mostly trading between 4.30 to 5.30, with mid-point at 4.80. Hence below 4.80 could also be considered "cheap" relative to past 3 yrs of stock price performance.

Stock price has been "cheap" for almost 5 yrs liow. Everyone knows its cheap. But why is it still cheap after so long?

Charlie Munger: "Every Time You Hear 'EBITDA’, Substitute It With ‘Bull**** Earnings' ”

Now USA operations are running at a net loss. There is no P.E ratio. They can plan n plan, but need to secure NYC casino license first then got story theme to IPO mah ... so we need to wait

Thick support zone from 4.60 to 4.66. Currently, the stock price is supported by previous catalyst which is Q1's RM588m earnings. Investors these days are quite short term they want to see corporate news that can make immediate strong contribution to bottomline. Wait for next QR liow hopefully it can continue to be the next catalyst. But from previous years' experience, there were quite a number of times GenS showed good Q results but GenB Q results did not reciprocate. UK & Egypt operation quite hopeless revenue and EBITA margin very low. USA operation is the wild card here with huge amortisation and interest charges, which has been a huge drag to overall group earnings performance.

Post removed.Why?

Posted by AngTayKor > 3 weeks ago | Report Abuse

Normal punters entering LKT's casino de bursa stocks have little chance to outsmart the whale n make some trading profit. If you are an experienced, sharp n cunning trader, you can steal some crumbs from the whale's lunch, else you become the whale's lunch.
--------------


This Genting whale can be very cunning n tricky. Expect the unexpected.

Posted by Michaelchan2024 > 2 days ago | Report Abuse
Good news.. 5.00 mari marii
---------

Couple of days ago still cheering for 5.00. Looks like heading towards my target support zone

Posted by Balian de Ibelin > 1 minute ago | Report Abuse

Sometimes a Guaranteed 30 sen profits very short term from GenM is way better.
Rather than a pie in sky from Genting.

Trouble free money in bag.
--------------


@Balian, my Taurx position is sitting on USD30m profit as of now. Trouble free money in bag, Immediately Buy Immediately Huat. Every investor / trader must know very very clearly what they are doing.

Posted by AngTayKor > 2023-07-04 12:41 | Report Abuse

........... HMTM works so beautifully.

1. HMTM already proven in phase 3 it can totally halt AD cognitive decline + 20% improvement in cognitive scores VS Lecanemab's 27% slowdown in decline but continue to decline at 73%.

2. HMTM has minimal side effects VS high brain bleeding chances including numerous death cases for Lecanemab

3. HMTM slows down brain atrophy (shrinkage) VS Lecanemab's accelerated brain shrinkage. This is definitely going in the wrong direction of how a good AD drug shd perform. ATK is expecting major efficacy and safety fiascos for Lecanemab in future.

4. HMTM at USD10k/ year VS Lecanemab's USD26k/yr treatment cost.

5, HMTM orally taken drug twice a day at home VS Lecanemab's twice a month infusion (like kidney dialysis) in hospital with multiple brain scans required for constant costly monitoring for ARIA.
-----------------

Posted by AngTayKor > 2023-10-25 12:46 | Report Abuse

@TAUkay, some years ago Prof CW still thinking abt USD3K treatment cost. I shot back at him during AGM that nobody will pity us if we fail so we dont have to do subsidised treatment cost charity here. He better not say this price to any media and shoot our own foot. Low treatment cost = Low grand jackpot pricing. Me as a shareholder waiting for grand jackpot for years, so dont short change us. The USD10k figure was due to Medicare drug reimbursement issues. But whats the limit here? The sky is the limit for us. We dont need to do those numerous PET scans and MRI scans, bi-weekly 2 hr intravenous drug delivery, constant monitoring for ARIAs by neurologists, etc. All these can add up tens of thousands on top of amyloid drug cost. Its crazy to use them, just go back to the good old aricept that is much safer and works much better at 2% of these amyloid treatment cost la. Thanks to Aducanumab's USD56K initial pricing, rising tide lift all boats. USD10k treatment cost VS USD270k total economic cost per AD patient. I bet ICER will give us a drug treatment value of at least USD50K to 70K. HMTM can totally halt disease progression + reverse it.
**************


The real cost of using lecanemab shd be somewhere close to USD50k yearly after including multiple PET and MRI scans, cost of bi-weekly intravenous deliveries followed by neuro consultations etc. For HMTM, there is no need for PET/MRI scans + more neuro consultations. Just take the blue pills go home and consume them yourself daily. If pricing HMTM at 50% discount (USD13k yearly) compared to lecanemab's USD26k yearly drug cost, is not doing justice to HMTM.

Posted by Balian de Ibelin > 1 hour ago | Report Abuse

Together ...........maybe with ATK help ...........we can SHORT Genting down to 4.40
------------

ATK already bet showhand (via taurx) that this stock will shoot to ATH above rm10.

Posted by AngTayKor > 3 weeks ago | Report Abuse

Normal punters entering LKT's casino de bursa stocks have little chance to outsmart the whale n make some trading profit. If you are an experienced, sharp n cunning trader, you can steal some crumbs from the whale's lunch, else you become the whale's lunch.
--------------



Stock trading is inherently a risky endeavor. Most amateurs will lose money. You need to be the top 10% to make money consistently. The top 2% are the ones making most of the money.

Posted by AngTayKor > 2024-01-27 02:13 | Report Abuse

Posted by Kikilala3188 > | Report Abuse
Taurx when will it be announcing? Especially U.K. FDA approval
---------------

ATK: UK MHRA's final decision on CA is unlikely to be within 2024. We still have to file in more submissions which will take abt 5 to 6 months to complete it, followed by another 6 to 9 months for the regulator's final decision.

FDA delayed our Type C meeting request (supposed to be end Jan, before Taurx AGM on 6 Feb @6pm). We are not even sure if FDA will agree to consider HMTM using the Accelerated Approval pathway. If yes, I think FDA's final decision for AA will probably be at least 1.5yrs away.
--------------

Posted by AngTayKor > 2 weeks ago | Report Abuse

Posted by neohts > | Report Abuse
Ask TauRX status, when can get approval?
---------

ATK: UAE CA end of 2024. UK, USA, EU CAs 2025 liow.

---------------
Posted by Balian de Ibelin > 4 hours ago | Report Abuse
Taurx decision anytime soon.
This is a gambling buy for the Shoot Up!!
Which other counter in BURSA right now today can give you this Gambling Buy?
All in, Sell all your Birkin bags to buy Genting.
--------------


Already posted the timeline here since Jan 2024. Things will change, usually delays and not earlier. Currently, my anticipated FDA AA decision is somewhere late 2025.

Please la @Diam88, my RPT articles and posts are in response to @tkkiong's posts of bringing up past RPTs. Even @Riaz constantly brought it up. The truth is often hard to swallow, history lessons often forgotten fast. I have already publicly declared here that i have no position in this stock. Being a shareholder of Taurx, my interests are aligned with GenB. Only amateurs think that posting here will move the stock price. I made several millions in profit from trading this stock from 2020 to 2023 with trade success rate between 80 to 90%. I dont have to resort to low end cheap tactics to scare people here, hoping to buy cheap. Or do nonstop yapping bullish things here hoping to sell high. Im confident of my own trading skills. I do hope that all of you huat from investing / trading this stock.

Posted by Michaelchan2024 > 5 minutes ago | Report Abuse
https://www.thestar.com.my/business/business-news/2024/05/29/ytl-power-unit-raises-stake-in-ranhill-triggers-mto
The proposed acquisition by YTL Power and SIPP Power raises concerns due to the substantial 36.62% discount over the last traded price of Ranhill. This significant undervaluation could indicate underlying issues with Ranhill's financial health or market perception.
--------------


"KUALA LUMPUR: YTL Power International Bhd’s 70%-owned subsidiary SIPP Power Sdn Bhd has agreed to a RM405.18mil deal for about 31.42% equity in Ranhill Utilities Bhd from Tan Sri Hamdan Mohamad and related entities Hamdan (L) Foundation and Hamdan Inc (Labuan) Pte Ltd."


@Michael, was the YTL and Tan Sri Hamdan Mohamad's deal a related party transaction? Seems like YTL's corporate action of buying assets at discounted price benefiting fellow shareholders of their own YTL listco.

Yes its old news on previous RPTs, sorry for opening old wounds since ER & GHK RPT episodes still being discussed here on i3.

Lim family bought cruise biz from listcos at lowest allowable price. Average cost usd0.42/share, sold to Lim family at usd0.29/share. LKT ah LKT....

https://www.thestar.com.my/business/business-news/2016/09/30/genting-malaysia-unit-sells-genting-hk-stake-at-lowest-sanctioned-price